Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYNERGY: Custirsen in mCRPC
NCT01188187Phase 3Completed
- Sponsor
- Achieve Life Sciences
- Start
- Nov 2010
- Primary completion
- Feb 2014
- Modality
- Small Interfering RNA (siRNA), Modified DNA Oligonucleotides, Single-strand DNA
- Countries
- 12
01
Overview
A Phase 3 trial of custirsen in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Achieve Life Sciences. Started Nov 2010; status: completed.
02
Drugs
custirsen
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT01188187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188187.